30
Participants
Start Date
August 31, 2007
Primary Completion Date
December 31, 2011
Study Completion Date
December 31, 2011
Imatinib Mesylate
In initial phase, patients will be treated with Gleevec 400 mg daily for 12 months. In the extension phase, patients will be treated with Gleevec 400 mg daily for 27 months.
Hospital for Special Surgery, New York
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Hospital for Special Surgery, New York
OTHER